Lung metastasis is a leading cause of cancer-related deaths. Here, we show that intranasal delivery of our engineered CpG-coated tumor antigen (Tag)-encapsulated nanoparticles (NPs)—nasal nano-vaccine—significantly reduced lung colonization by intravenous challenge of an extra-pulmonary tumor. Protection against tumor-cell lung colonization was linked to the induction of localized mucosal-associated effector and resident memory T cells as well as increased bronchiolar alveolar lavage-fluid IgA and serum IgG antibody responses. The nasal nano-vaccine-induced T-cell-mediated antitumor mucosal immune response was shown to increase tumor-specific production of IFN-γ and granzyme B by lung-derived CD8+ T cells. These findings demonstrate that our engineered nasal nano-vaccine has the potential to be used as a prophylactic approach prior to the seeding of tumors in the lungs, and thereby prevent overt lung metastases from existing extra pulmonary tumors.
The lung is one of the most frequent sites of cancer metastasis. Because metastatic lung disease is usually associated with poor survivorship, decreasing secondary lung metastasis will decrease morbidity and mortality associated with cancer. Mitigating tumor immunosurveillance at metastatic sites such as the lung is essential for tumor progression and metastasis. As such, tumors developing elsewhere in the body take advantage of the natural tolerogenicity of the lung to establish immunosuppressive niches via tumor burden induce pre-metastatic niche formation to support lung metastasis. Here we tested the ability of an intranasal nano-vaccine administration to prevent the seeding of tumor cells in the lungs by pre-emptying tumor burden induced immunosuppression. Our hypothesis is that intranasal administration of cancer nano-vaccine will prevent secondary lung metastasis from an existing primary tumor. Because breast cancer is the one of the primary tumors with high propensity to metastasize to the lung, we used the syngeneic mouse breast tumor model to test our hypothesis. Our results showed that intranasal administration of our engineered nano-vaccine protected the lungs of female BALB/c mice from secondary lung metastasis after orthotopic implantation of murine 4T1 tumors. The protection was as a result of nano-vaccine induced antitumor immunity in the lungs. Mice that received the intranasal nano-vaccine had increased frequency of effector T-cells and increase accumulation of lung resident memory T-cell in their lungs. This coincided with increased frequency of IFN-g and granzyme B producing CD8+ T-cells following ex-vivo restimulation of lymphocytes from the lungs of previously immunized mice with tumor cell. These results demonstrate that cancer vaccines can still be part of an integrated cancer therapy where they can be used as a prophylactic approach to prevent secondary lung metastasis. Citation Format: Michael A Donkor, Jamie Choe, Byron Quinn, Harlan P Jones. Intranasal nanoparticulate PLGA cancer vaccine administration prevents secondary lung metastasis [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl):Abstract nr A53.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.